Brian McVeigh, Code Biotherapeutics CEO (Code)
No AAV? No problem. Code Biotherapeutics joins the search for a non-viral gene therapy
Brian McVeigh’s wake-up call came one morning in the form of a LinkedIn notification congratulating him for 25 years at GlaxoSmithKline.
“I was like, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
